Skip to main content
Industry News
AZ's osimertinib gains breakthrough therapy tag

AstraZeneca's Tagrisso, or osimertinib, has been tagged for accelerated review after receiving breakthrough therapy status from the FDA. The drug is an adjuvant treatment for patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer who have undergone complete tumor resection.

Full Story: